The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Diagnosis and Management of Multiple Myeloma: A Review
Abstract
IMPORTANCE: Multiple myeloma is a hematologic malignancy characterized by presence of abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth causing destructive bone lesions, kidney injury, anemia, and hypercalcemia. Multiple myeloma is diagnosed in an estimated 34 920 people in the US and in approximately 588 161 people worldwide each year. OBSERVATIONS: Among patients with multiple myeloma, approximately 73% have anemia, 79% have osteolytic bone disease, and 19% have acute kidney injury at the time of presentation. Evaluation of patients with possible multiple myeloma includes measurement of hemoglobin, serum creatinine, serum calcium, and serum free light chain levels; serum protein electrophoresis with immunofixation; 24-hour urine protein electrophoresis; and full-body skeletal imaging with computed tomography, positron emission tomography, or magnetic resonance imaging. The Revised International Staging System combines data from the serum biomarkers β2 microglobulin, albumin, and lactate dehydrogenase in conjunction with malignant plasma cell genomic features found on fluorescence in situ hybridization-t(4;14), del(17p), and t(14;16)-to assess estimated progression-free survival and overall survival. At diagnosis, 28% of patients are classified as having Revised International Staging stage I multiple myeloma, and these patients have a median 5-year survival of 82%. Among all patients with multiple myeloma, standard first-line (induction) therapy consists of a combination of an injectable proteasome inhibitor (ie, bortezomib), an oral immunomodulatory agent (ie, lenalidomide), and dexamethasone and is associated with median progression-free survival of 41 months, compared with historical reports of 8.5 months without therapy. This induction therapy combined with autologous hematopoietic stem cell transplantation followed by maintenance lenalidomide is standard of care for eligible patients. CONCLUSIONS AND RELEVANCE: Approximately 34 920 people in the US and 155 688 people worldwide are diagnosed with multiple myeloma each year. Induction therapy with an injectable proteasome inhibitor, an oral immunomodulatory agent and dexamethasone followed by treatment with autologous hematopoietic stem cell transplantation, and maintenance therapy with lenalidomide are among the treatments considered standard care for eligible patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
Randomized trial of lenalidomide versus observation in smoldering multiple myeloma
Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., O’Brien, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01740 · Cited by 908
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationMiguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 801
San-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
(2020) · OncoTargets and Therapy · doi:10.2147/ott · Cited by 787
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 693
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Clinical and biologic implications of recurrent genomic aberrations in myeloma
Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., Dewald, G. W., Van Ness, B., Van Wier, S. A., Henderson, K. J., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3017 · Cited by 660
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709974 · Cited by 647
Attal, M., Richardson, P. G., Rajkumar, S. V., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 645
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805762 · Cited by 535
Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30309-2 · Cited by 516
Raje, N., Terpos, E., Willenbacher, W., Shimizu, K., García-Sanz, R., Durie, B., Legieć, W., Krejčí, M., Laribi, K., Zhu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30072-x · Cited by 449
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 446
Dimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W.-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30578-8 · Cited by 401
Usmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 394
Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 392
Fernández de Larrea, C., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S., Vesole, D. H., Hajek, R., San Miguel, J. F., Sezer, O., Sonneveld, P., et al. (2013) · Leukemia · doi:10.1038/leu.2012.336 · Cited by 382
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Hillengass, J., Fechtner, K., Weber, M.-A., Bäuerle, T., Ayyaz, S., Heiss, C., Hielscher, T., Moehler, T. M., Egerer, G., Neben, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5356 · Cited by 381
Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 381
Cancer Risk Among Firefighters: A Review and Meta-analysis of 32 Studies
LeMasters, G. K., Genaidy, A. M., Succop, P., Deddens, J., Sobeih, T., Barriera-Viruet, H., Dunning, K., & Lockey, J. (2006) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000246229.68697.90 · Cited by 370
Dimopoulos, M. A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 363
Zamagni, E., Nanni, C., Patriarca, F., Englaro, E., Castellucci, P., Geatti, O., Tosi, P., Tacchetti, P., Cangini, D., Perrone, G., et al. (2007) · Haematologica · doi:10.3324/haematol.10554 · Cited by 354
Rajkumar, S. V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
Fonseca, R., Blood, E. A., Oken, M. M., Kyle, R. A., Dewald, G. W., Bailey, R. J., Van Wier, S. A., Henderson, K. J., Hoyer, J. D., Harrington, D., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3735 · Cited by 340
Grosicki, S., Simonova, M., Spicka, I., Pour, L., Kriachok, I., Gavriatopoulou, M., Pylypenko, H., Auner, H. W., Leleu, X., Doronin, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32292-3 · Cited by 335
Trends in overall survival and costs of multiple myeloma, 2000–2014
Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., & Richardson, P. (2017) · Leukemia · doi:10.1038/leu.2016.380 · Cited by 323
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Krönke, J., Facon, T., Salnikov, A. V., Lesley, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02657 · Cited by 304
Krishnan, A., Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70243-1 · Cited by 274
Stadtmauer, E. A., Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00685 · Cited by 259
Durie, B. G. M., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0311-8 · Cited by 253
Trudel, S., Lendvai, N., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G., Anderson, L. D., Sutherland, H. J., Yong, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30576-x · Cited by 250
Self-citationKumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N., Singh, A. K., Parker, T. L., Menter, A., Yang, X., Parsons, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30452-6 · Cited by 245
Bahlis, N. J., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kim, K., Takezako, N., Moreau, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0711-6 · Cited by 238
Joseph, N. S., Kaufman, J. L., Dhodapkar, M. V., Hofmeister, C. C., Almaula, D. K., Heffner, L. T., Gupta, V. A., Boise, L. H., Lonial, S., & Nooka, A. K. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02515 · Cited by 238
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Weinhold, N., Ashby, C., Rasche, L., Chavan, S. S., Stein, C., Stephens, O. W., Tytarenko, R., Bauer, M. A., Meissner, T., Deshpande, S., et al. (2016) · Blood · doi:10.1182/blood-2016-06-723007 · Cited by 217
Tsang, R. W., Campbell, B. A., Goda, J. S., Kelsey, C. R., Kirova, Y. M., Parikh, R. R., Ng, A. K., Ricardi, U., Suh, C.-O., Mauch, P. M., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.05.009 · Cited by 213
Trudel, S., Lendvai, N., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G., Hoos, A., Gupta, I., Bragulat, V., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0196-6 · Cited by 213
Self-citationDimopoulos, M. A., San-Miguel, J., Belch, A., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kim, K., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194282 · Cited by 210
Leleu, X., Attal, M., Arnulf, B., Moreau, P., Traulle, C., Marit, G., Mathiot, C., Petillon, M. O., Macro, M., Roussel, M., et al. (2013) · Blood · doi:10.1182/blood-2012-09-452375 · Cited by 206
Moreau, P., Mateos, M.-V., Berenson, J. R., Weisel, K., Lazzaro, A., Song, K., Dimopoulos, M. A., Huang, M., Zahlten-Kumeli, A., & Stewart, A. K. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30354-1 · Cited by 206
Bjorklund, C. C., Kang, J., Amatangelo, M., Polonskaia, A., Katz, M., Chiu, H., Couto, S., Wang, M., Ren, Y., Ortiz, M., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0620-8 · Cited by 205
Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle
Lightman, S. M., Utley, A., & Lee, K. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00965 · Cited by 202
Chang, H., Qi, C., Yi, Q.-L., Reece, D., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-04-1363 · Cited by 201
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., et al. (2018) · Leukemia · doi:10.1038/leu.2017.211 · Cited by 200
Nooka, A. K., Kaufman, J. L., Muppidi, S., Langston, A., Heffner, L. T., Gleason, C., Casbourne, D., Saxe, D., Boise, L. H., & Lonial, S. (2014) · Leukemia · doi:10.1038/leu.2013.335 · Cited by 195
Myeloma as a model for the process of metastasis: implications for therapy
Ghobrial, I. M. (2012) · Blood · doi:10.1182/blood-2012-01-379024 · Cited by 188
Hillengass, J., Moulopoulos, L. A., Delorme, S., Koutoulidis, V, Mosebach, J., Hielscher, T., Drake, M., Rajkumar, S. V., Oestergaard, B., Abildgaard, N., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.78 · Cited by 178
Holstein, S. A., Jung, S.-H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30140-0 · Cited by 173
Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
Zhou, L., Yu, Q., Wei, G., Wang, L., Huang, Y., Hu, K., Hu, Y., & Huang, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08280-y · Cited by 170
Drayson, M. T., Bowcock, S., Planche, T., Iqbal, G., Pratt, G., Yong, K., Wood, J., Raynes, K., Higgins, H., Dawkins, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30506-6 · Cited by 167
Morgan, G. J., Child, J. A., Gregory, W. M., Szubert, A. J., Cocks, K., Bell, S. E., Navarro-Coy, N., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70157-7 · Cited by 165
Association of response endpoints with survival outcomes in multiple myeloma
Lonial, S., & Anderson, K. C. (2014) · Leukemia · doi:10.1038/leu.2013.220 · Cited by 162
Schmidt, T. M., Barwick, B. G., Joseph, N., Heffner, L. T., Hofmeister, C. C., Bernal, L., Dhodapkar, M. V., Gupta, V. A., Jaye, D. L., Wu, J., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0254-0 · Cited by 162
Mateos, M.-V., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W., Corradini, P., Min, C.-K., Medvedova, E., Weisel, K., et al. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.623 · Cited by 160
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw606 · Cited by 159
Bisphosphonates in multiple myeloma: an updated network meta-analysis
Mhaskar, R. S., Kumar, A., Miladinović, B., & Djulbegović, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188.pub4 · Cited by 159
Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series
McDonald, R. J., Trout, A. T., Gray, L. A., Dispenzieri, A. A., Thielen, K. R., & Kallmes, D. F. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0918 · Cited by 137
Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
Bahlis, N. J., & Lazarus, H. M. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705395 · Cited by 135
Dioxin Exposure and Cancer Risk: A 15-Year Mortality Study after the “Seveso Accident”
Bertazzi, P. A., Zocchetti, C., GUERCILENA, S., Consonni, D., Tironi, A., Landi, M. T., & Pesatori, A. C. (1997) · Epidemiology · doi:10.1097/00001648-199711000-00010 · Cited by 135
Evaluation of monoclonal gammopathies in the “well” elderly
Crawford, J., Eye, M. K., & Cohen, H. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90375-5 · Cited by 134
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 121
Ross, F. M., Chiecchio, L., Dagrada, G. P., Protheroe, R. K. M., Stockley, D. M., Harrison, C. J., Cross, N. C. P., Szubert, A. J., Drayson, M. T., Morgan, G. J., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016329 · Cited by 101
Gagelmann, N., Eikema, D.-J., Köster, L., Caillot, D., Pioltelli, P. E., Lleonart, J. B., Reményi, P., Blaise, D., Schaap, N. P., Trněný, M., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.07.004 · Cited by 95
Dimopoulos, M. A., Špıčka, I., Quach, H., Oriol, A., Hájek, R., Garg, M. K., Beksaç, M., Bringhen, S., Katodritou, E., Chng, W. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02060 · Cited by 84
How I treat fragile myeloma patients
Larocca, A., & Palumbo, A. P. (2015) · Blood · doi:10.1182/blood-2015-05-612960 · Cited by 79
Durable remission with salvage second autotransplants in patients with multiple myeloma
Shah, N., Ahmed, F., Bashir, Q., Qureshi, S., Dinh, Y. T., Rondón, G., Wen, S., Thall, P. F., Khan, H., Giralt, S., et al. (2011) · Cancer · doi:10.1002/cncr.26662 · Cited by 78
Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
Lakshman, A., Singh, P. P., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dingli, D., Hwa, Y. L., Fonder, A. L., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24954 · Cited by 70
Prevalence, incidence and survival of smoldering multiple myeloma in the United States
Ravindran, A., Bartley, A. C., Holton, S. J., Gonsalves, W. I., Kapoor, P., Siddiqui, M. A., Hashmi, S. K., Marshall, A. L., Ashrani, A. A., Dispenzieri, A. A., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.100 · Cited by 67
How I manage the toxicities of myeloma drugs
Delforge, M., & Ludwig, H. (2017) · Blood · doi:10.1182/blood-2017-01-725705 · Cited by 57
Natural history of multiple myeloma with de novo del(17p)
Lakshman, A., Painuly, U., Rajkumar, S. V., Ketterling, R. P., Kapoor, P., Greipp, P. T., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0191-y · Cited by 57
Landgren, O., Zeig-Owens, R., Giricz, O., Goldfarb, D., Murata, K., Thoren, K., Ramanathan, L., Hultcrantz, M., Dogan, A., Nwankwo, G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0509 · Cited by 55
Dhakal, B., Patel, S. S., Girnius, S. K., Bachegowda, L., Fraser, R. A., Dávila, O., Kanate, A. S., Assal, A., Hanbali, A. S., Bashey, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0830-0 · Cited by 48
Self-citationIs aggressive chemotherapy more effective in the treatment of plasma cell myeloma?
Bergsagel, D. E. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90001-1 · Cited by 47
Birmann, B. M., Andreotti, G., Roos, A. J. D., Camp, N. J., Chiu, B. C. ‐., Spinelli, J. J., Becker, N., Benhaïm-Luzon, V., Bhatti, P., Boffetta, P., et al. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0762-t · Cited by 46
Cowan, A. J., Baldomero, H., Atsuta, Y., Mikhael, J. R., Aljurf, M. D., Seber, A., Greinix, H., Koh, M., Worel, N., Libby, E. N., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.08.018 · Cited by 35
Self-citationMellors, P. W., Binder, M., Ketterling, R. P., Greipp, P. T., Baughn, L. B., Peterson, J. F., Jevremović, D., Pearce, K. E., Buadi, F. K., Lacy, M. Q., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001275 · Cited by 34
Chan, H. S. H., Phillips, M. J., Maganti, M. D., Farooki, S., Rodriguez, G. P., Masih‐Khan, E., Chen, C. I., Prica, A. A., Reece, D. E., Tiedemann, R. E., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.009 · Cited by 10
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00966-9 · Cited by 113
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Yin, Z., Lv, Y., Deng, L., Li, G., Ou, R., Chen, L., Zhu, Y., Zhong, Q., Liu, Z., Huang, J., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.04.003 · Cited by 47
Lutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp6667 · Cited by 25
Metadata
- Authors
- Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-02-01
- Volume
- 327
- Issue
- 5
- Pages
- 464
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4210734847
- Cited by
- 1,029
- References
- 102
- FWCI
- 131.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.